

**Predicting the presence of breast cancer using circulating small RNAs, including those in
the extracellular vesicles**

Authors: Yumiko Koi^{1,2}, Yasuhiro Tsutani², Yukie Nishiyama³, Daisuke Ueda^{1,2}, Yuta Ibuki^{1,2},
Shinsuke Sasada², Tomoyuki Akita⁴, Norio Masumoto², Takayuki Kadoya², Yuki Yamamoto³,
Ryou-u Takahashi³, Junko Tanaka⁴, Morihito Okada², Hidetoshi Tahara^{3,5,*}

Institute Address: ¹Surgical Oncology, Division of Radiation Biology and Medicine, Graduate
School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan; ²Department
of Surgical Oncology, Research Center for Radiation Casualty Medicine, Research Institute for
Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan; ³ Department of
Cellular and Molecular Biology, Graduate School of Biomedical & Health Sciences, Hiroshima
University, Hiroshima, Japan; ⁴Department of Epidemiology, Infectious Disease Control and
Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University,
Hiroshima, Japan, ⁵Collaborative laboratory of Liquid Biopsy, Graduate School of Biomedical
& Health Sciences, Hiroshima university Hiroshima, 734-8553, Japan

Corresponding author: Prof. Hidetoshi Tahara, Department of Cellular and Molecular Biology,
Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan,
Kasumi 1-2-3, Minami-ku, Hiroshima 734-8553, Japan. Phone: +81-82-257-5290, E-mail:

toshi@hiroshima-u.ac.jp

Word count: 6537 words

Number of tables/figures: 9

Quantity of supporting information: not applicable

Abstract

Emerging evidence indicates that small RNAs, including microRNAs (miRNAs) and their isoforms (isomiRs), and transfer RNA fragments (tRFs), are differently expressed in breast cancer (BC) and can be detected in blood circulation. Circulating small RNAs and small RNAs in extracellular vesicles (EVs) have emerged as ideal markers in small RNA-based applications for cancer detection. In this study, we first performed small RNA sequencing to assess the expression of circulating small RNAs in the serum of BC patients and cancer-free individuals (control). Expression of 3 small RNAs, namely isomiR of miR-21-5p (3' addition C), miR-23a-3p and tRF-Lys (TTT), was significantly higher in BC samples, and was validated by small RNA sequencing in an independent cohort. Our constructed model using 3 small RNAs showed high diagnostic accuracy with an AUC of 0.92, and discriminated early-stage BCs at stage 0 from control. To test the possibility that these small RNAs are released from cancer cells, we next examined EVs from the serum of BC patients and control. Two of the 3 candidate small RNAs were identified, and shown to abundant in EVs of BC patients. Interestingly, these 2 small RNAs are also more abundantly detected in culture media of breast cancer cell lines (MCF-7 and MDA-MB-231). The same tendency in selective elevation seen in total serum, serum EV, and EV derived from cell culture media may indicate that the efficiency of this model using total serum of patients. These findings indicate that small RNAs serve as significant

biomarkers for BC detection.

Keywords: extracellular vesicles; small RNA; biomarker; breast cancer; serum

Abbreviations: BC: breast cancer; ER: estrogen receptor; FC: fold change; FISH: fluorescence

in situ hybridization; HER2: human epidermal growth factor receptor 2; L: lengths; N: control;

PR: progesterone receptor

Introduction

Breast cancer (BC) is one of the most common cancers among women worldwide (1). Although mammography is commonly used for BC screening (2), it has hampered by the occurrence of false-positive results, which might lead to additional imaging or tumor biopsy (3, 4). In addition, the sensitivity of mammography is decreased in younger women or women with dense breast tissue (5, 6). Asian women have relatively high breast density, and are at particular need of methods for BC detection that overcome these problems (7).

Extracellular vesicles (EVs) are membranous vesicles secreted from cells to the extracellular environment which contain nucleic acid, proteins, and lipids (8). EVs can be classified into various types according to size and mode of biogenesis (9). Exosomes are nano-sized EVs (30-150 nm) originating from the endocytic pathway (10). EVs, especially exosomes, have been found to play essential roles in intercellular communication through their cargo. EV components differ by releasing cell type, and have therefore been investigated as markers for disease, including cancer. One example is EV-encapsulated small RNAs (EV small RNAs) (8).

Small RNAs consist of multiple classes of short non-coding RNA (ncRNA) molecules that include microRNAs (miRNAs), transfer RNA fragments (tRFs), and other RNA fragments generated from Y RNAs; miscellaneous RNAs (misc RNAs); and others. (11). Recent results have shown that miRNAs can be divided into canonical miRNAs and miRNA isoforms

(isomiRs); this latter type is differentiated from canonical miRNAs by variations in length and/or sequence via the addition or deletion of nucleotides at the 5' or 3' end, or both (12, 13).

Small RNAs circulate stably in blood (circulating small RNAs) and can be isolated from blood samples (14, 15).

Small RNAs play essential roles in gene regulation at the post-transcriptional level (16, 17). It is generally accepted that small RNAs are crucial to biological processes and that their dysregulation results in disease development (15, 18). Indeed, aberrant expression of miRNAs is associated with various cancers (19, 20), and expression profiles of circulating miRNA or EV miRNAs have been recently investigated as potential biomarkers for BC detection (21-25).

Furthermore, the distribution and abundance of isomiRs, tRFs, and other small RNA fragments have been shown to differ non-randomly depending on disease status (18, 26-29). Significant levels of these small RNA fragments as well as miRNAs can serve as precise biomarkers for cancer detection. Surprisingly, however, almost no investigation of these fragments in patients with BC has yet been reported.

In this study, we employed next generation sequencing (NGS) to identify biomarkers by profiling multiple classes of small RNAs in serum from BC patients. By comparing the small RNA signature with that of cancer-free individuals, we aimed to detect specific circulating small RNAs that can indicate the presence of BC. In addition, we also attempted to construct an NGS-

based diagnostic model using small RNAs for BC detection. Finally, we evaluated the expression pattern of EV small RNAs in serum from BC patients and in cell culture media of BC cell lines to investigate the relation between circulating small RNA and EV small RNAs.

Materials and Methods

Ethics statement

This study was approved by the Institutional Review Board of Hiroshima University Hospital.

Written informed consent was obtained from all participants before enrollment.

Participants

Seventy-eight patients with newly diagnosed BC at clinical Stage (cStage) 0-III at Hiroshima University Hospital from November 2016 to August 2017 were included in the BC group. In parallel, 72 cancer-free female individuals were recruited in the Control (N) group. Participants of the N group had undergone screening mammography or breast ultrasound sonography within the previous 2 years at Okimi-Hamai Hospital to ensure their BC-free status before enrollment.

We excluded patients with distant metastasis in order to focus on finding biomarkers for early detection. Participants with a previous history of any cancer or with a current inflammatory condition were also ineligible.

Carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 15-3, which are traditional serum markers for BC monitoring, were assessed in the BC group before the start of treatment. All BCs were histopathologically diagnosed using primary tumor specimens, with staging done using the 8th edition of the TNM classification of malignant tumors (30). For invasive BC tumors, we evaluated the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) by immunohistochemistry (IHC). Tumors were considered to be ER- or PR- positive when $\geq 1\%$ of cells were stained. HER2 expression was scored according to the guidelines of the American Society of Clinical Oncology/College of American Pathologists (31). Scores of 2+ were further assessed via fluorescence in situ hybridization (FISH). HER2 positivity was defined as either IHC 3+ or IHC 2+ and HER2 gene amplification by FISH (HER2/CEP ratio > 2.0).

Serum sample collection and small RNA extraction

Serum was isolated by centrifugation of the whole blood twice at 3500 rpm at room temperature (25 °C) for 10 minutes followed by 12000 g at 4 °C for 10 minutes. Serum samples were transferred to RNase-free tubes and stored at -80 °C until further use.

Circulating small RNAs and EV small RNAs were extracted from 250 μ L of serum and EV samples using a miRNeasy Mini Kit (Qiagen, Crawley, West Sussex, UK) in accordance with

the manufacturer's protocol. Quantification and integrity of the obtained small RNAs were assessed with an Agilent 2100 Bioanalyzer (Agilent Technology, CA, USA) using RNA 6000 pico chips in accordance with the manufacturer's instructions to confirm the amount of starting extracted small RNAs was sufficient for library construction.

Isolation of EVs

EVs were isolated from 100 μ L of serum and 10 mL of cell supernatant using a Total Exosome Isolation kit (Invitrogen, Carlsbad, CA, USA) in accordance with the manufacturer's protocol. Pellets containing EVs were dissolved in 50 μ L of phosphate-buffered saline (PBS) which had been filtered once through a 0.22- μ m-pore filter (Steriflip SCGP00525, Millipore, Billerica MA). To evaluate small RNA profiles within serum-derived EVs, 32 samples in the BC group and 20 samples in the N group were randomly selected. Analysis of EV samples from cell culture media was performed in duplicate.

Characterization of EVs

Following EV isolation, we examined the size distribution and concentration of particles using qNANO (Izon, Cambridge, MA, USA) and analyzed the data with software provided by Izon (version 3.2). Protein concentrations were determined using a Micro BCA Protein Assay Kit

(Thermo Fischer). The presence of exosome markers CD9 (CAC-SHI-EXO-M01, clone 12A12, Cosmo Bio, Tokyo, Japan) and TSG-101 (5377-1, clone EPR7131(B), Abcam, Cambridge, MA, USA) and lipoprotein marker anti-apolipoprotein B-100 (SC-13538, Santa Cruz Biotechnology, Santa Cruz, CA) was confirmed by western blotting. Transmission electron microscopy (TEM) analysis was performed for morphological characterization of EVs as described previously (32). Carbon-film grids that EVs applied to were examined with a HITACHI H-7600 TEM (Hitachi High-Technologies Corporation, Tokyo, Japan) at Hanaichi UltraStructure Research (Aichi, Japan).

Cell culture

Human BC cell lines MCF7 and MDA-MB-231 and normal human breast epithelial telomerase immortalized cells 184-h TERT were cultivated to isolate EVs. BC cells were cultured in Dulbecco's minimal essential medium (DMEM) supplemented with 10% fetal bovine serum (FBS; Gibco/Thermo Fisher Scientific, Grand Island, NY, USA) and 1% penicillin/streptomycin (Corning/Mediatech, Inc. Manassas, VA, USA) in accordance with the suppliers' recommendations. After the cells were washed with PBS, the culture medium was replaced with FBS-free advanced DMEM and collected after 48 hours' incubation for EV isolation. 184-h TERT cells were cultivated in serum-free Mammary Epithelial Basal Medium

(Lonza Inc. Walkersville, MD, USA) supplemented with Mammary Epithelial Cell Growth Medium SingleQuots™ Kit (Lonza Inc.) in accordance with the supplier's recommendations. After the cells were washed with PBS, the culture medium was collected after 48 hours' incubation. Before isolation of EVs, collected cell supernatant was centrifuged at $2,000 \times g$ for 30 minutes at $4\text{ }^{\circ}\text{C}$ and $12,000 \times g$ for 30 minutes at $4\text{ }^{\circ}\text{C}$ to remove dead cells and cellular debris and large vesicles were discarded. After centrifugation, the supernatant was filtered through a $0.22\text{-}\mu\text{m}$ -pore filter. All cells were incubated in a humidified chamber at $37\text{ }^{\circ}\text{C}$ and 5% CO_2 .

Library preparation and small RNA sequencing

Libraries for sequencing analysis were generated from $4\text{ }\mu\text{L}$ of small RNA per sample. The barcoded libraries were constructed using an Ion Total RNA-Seq Kit v2 (Thermo Fisher) and Ion Xpress RNA-Seq Barcode 01-16 Kit (Thermo Fisher) in accordance with the manufacturer's instructions. All libraries were size-selected using the Blue Pippin system (Sage Science; Beverly, MA, USA) to reduce low molecular weight contamination and collect tight size distribution of cDNA fragments to improve the quality of analysis. We used a 3.0% agarose gel and set the range of selection from 88 to 112 base pairs to isolate cDNA fragments on the system. Quantification and integrity of the amplified cDNA were assessed with an Agilent 2100

Bioanalyzer (Agilent Technology) using high sensitivity chips in accordance with the manufacturer's instructions. The libraries were subsequently equalized to 100 pM. The Ion Chef™ System (Thermo Fisher) was used to deliver template preparation and chip loading. The libraries were delivered up to 400 base pairs. Sequencing was performed on an ION 540 chip for 160 cycles using an Ion 540 kit Chef (Life Technologies). All samples were sequenced on an Ion S5XL system (Thermo Fisher) in accordance with the manufacturer's instructions.

Sequencing analysis

The obtained sequence data were imported to a CLC Genomic Workbench 7 (CLCbio, Aarhus, Denmark) and analyzed. To normalize the measured reads, the resultant values were modified to reads per million (RPM) for the respective library. The normalized reads were annotated to miRBase version 21 (<http://www.mirbase.org/>) with high priority (33). Remaining reads were annotated to GtRNADB and GRCh38.p12 as reference (34-36).

Selection criteria for small RNA as biomarker candidates were as follows: (i) found in more than 90% of each sample; (ii) mean RPM in the BC group was above 1000; and (iii) presence of a significant fold change (more than 2.0-fold change for up-regulated small RNAs) compared to the N group.

Statistical analysis

Statistical analysis was done using the JMP® 12 software program (SAS Institute Inc., Cary, NC, USA), with the data presented as mean RPM. Group comparisons were performed using the t-test. Prediction performance of small RNAs was assessed using receiver operating characteristic (ROC) curves and area under the curve (AUC). The diagnostic accuracy was defined as the proportion of true positive with disease and true negative without disease in total participants. Significance threshold was set at $p < 0.05$.

Results

Participant characteristics

Figure 1 shows the flow chart for this study. Participants from each group were divided into two independent cohorts [BC (n=39) vs. N (n=36), respectively], one cohort for the selection of small RNA biomarker candidates (screening phase) and the second cohort for testing of biomarker candidates (validation phase). Characteristics of participants are summarized in Table 1.

Selection of circulating small RNA biomarker candidates

To determine differentially expressed circulating small RNAs in serum, we performed small RNA sequencing using samples from the screening phase and compared the expression level of

each small RNA identified between the BC and N group. The expression of 11 circulating small RNAs was significantly upregulated in the BC group compared to the N group and met the cut-off criteria that we set (Table 2). These small RNAs were then further evaluated in the validation phase as biomarker candidates.

Validation of circulating small RNA candidates

The differential expression of small RNA candidates was confirmed by NGS profiling analysis of the independent cohort used for the validation phase. Among the 11 small RNA candidates, 3 achieved reproducibility of our selection criteria with significant p-values, as shown in Figure 2. The expression levels of 1 canonical miRNA (miR-23a-3p) and 1 isomiRs [isomiR of miR-21-5p (3' addition C)] were significantly up-regulated in the BC group compared to the N group. In addition, expression of tRF-Lys (TTT) was also significantly higher in the BC group. Since no specific abbreviations have been established, we used temporary labels for the sake of convenience in this study, with tRF-Lys (TTT) for tRF having the sequence 5'-GCCCGGAUAGCUCAGUCGGUAGAGCAUCAGAC-3'.

IsomiR abundance

Expression levels of canonical miRNA and isomiRs differed between the BC and N groups.

Figure 3 shows the top 5 expression levels of the canonical miRNA and isomiRs of miR-21-5p and miR-23a-3p (Figure 3). For miR-21-5p, isomiR of miR-21-5p (3' addition C) was more abundant in serum samples from the BC group, and expression differed between the BC and N groups. For miR-23a-3p, in contrast, canonical miR-23a-3p showed the greatest difference in abundance between 2 groups.

Diagnostic accuracy of small RNAs

The diagnostic accuracy, including sensitivity and specificity, of each small RNA was assessed. As shown in Table 3, the combination of 3 small RNAs had the best diagnostic accuracy. Next, we established a discriminant model for BC detection with multiple regression analysis using the data obtained from screening phase. The model was calculated as follows: Score = -44.23+1.407* log₂(RPM of isomiR of miR-21-5p) +1.191 *log₂(RPM of miR-23a-3p) +1.396* log₂(RPM of tRF-Lys (TTT)). The cut-off point was set at 0. The potential of our model was evaluated using data from total participants. ROC curves revealed an AUC value for the combination model of these 3 small RNAs of 0.92 (Figure 4A). Moreover, the diagnostic accuracy of this combination model could also successfully discriminate Stage 0 breast cancer from the control group (Figure 4B). In addition, our model could detect BC irrespective of breast cancer subtypes (Figure 4C). IHC staining did not reveal any significant difference for

discrimination of our model, with or without stain-positivity (Figure 4D). Among 78 BC patients, the number of patients with CEA and CA15-3 levels above the normal limit was 1 (1.3%) and 3 (3.8%), respectively. In contrast, our constructed model showed a positivity of 92.0% (Figure 4C).

Evaluation of EV characteristics

TEM analysis revealed the isolated EVs had exosome-like structure in the size of approximately 150nm, within the expected range from the results of size distribution (Figure 5A). The isolated EVs had detectable CD9 and TSG101 as indicated by western blot analysis (Figure 5B). The size distribution of EVs is presented in Figure 5C; mode diameter was 89.7 nm (range: 75.9 - 403.7) in the BC samples and 87.8 nm (range: 76.1 – 368.6) in the N samples, suggesting that the main component of isolates were exosomes. The concentration of EVs ($\times 10^{11}$ particles/ml) was 8.05 in the BC group and 3.07 in the N group (Figure 5D). Lipoproteins for potential contamination were also detected in isolated EVs (Figure 5E).

Small RNA expression levels in serum EVs and EVs from cell culture media

To evaluate the expression levels of small RNAs within EVs, we analyzed small RNA profiling in EVs derived from serum. Among the 3 circulating small RNAs we identified as significantly

upregulated in the serum of BC patients, 2 miRNAs were contained in EVs at a significantly high level in the BC group (all, $p < 0.01$). In contrast, tRF-Lys (TTT) showed no significant difference in expression (Figure 6).

To identify enriched small RNAs in EVs from cells, we profiled small RNA expression in EVs derived from the cell culture media. EVs from BC cells contained all 3 small RNAs. Compared to small RNA expression levels in EVs from 184-h TERT cell media, 2 miRNAs were more enriched in EVs from the BC cell media. Further, tRF-Lys (TTT) levels were lower in EVs from the BC cell media than those from 184-h TERT cells (Figure 6).

Discussion

In this study, we identified discriminative small RNA expression in serum samples from BC patients using NGS. Comprehensive analysis revealed that the expression levels of 3 circulating small RNAs, namely isomiR of miR-21-5p (3' addition C), miR-23a-3p, and tRF-Lys (TTT), were significantly up-regulated in BC patients compared to cancer-free individuals, and might accordingly serve as novel diagnostic biomarkers for BC detection. Our constructed model using these 3 small RNAs provided high diagnostic performance with an AUC of 0.92. In addition, we evaluated EV small RNAs from serum and cell culture media to identify the abundance of each RNA in EVs. Two of the 3 small miRNAs were more abundantly included in

EVs of serum and cell culture media from BC compared to those from cancer-free individuals.

The association of dysregulation of miRNAs with cancer development is well established (37).

The use of miRNAs as cancer biomarkers is supported not only by their cancer-related biogenesis, but also by their high stability in peripheral blood. The use of a biofluid such as blood has the distinct advantages that it can be obtained non-invasively and repeatedly, and does not require organ-specific examinations such as mammography. Although the serum markers CEA and CA15-3 are clinically useful for BC monitoring, they are not recommended for BC detection because of their low sensitivity and specificity (38). These factors warrant exploration for possible blood biomarkers for BC detection, and explain the interest shown in circulating miRNAs (39-42).

Recent studies have revealed that isomiRs are generated from miRNA processing of canonical miRNAs and that canonical miRNA are not always expressed as abundantly as isomiRs of the same family (27). Moreover, several studies have reported that isomiRs have active roles and thus should not be ignored (43-45). Attempts to evaluate the expression of individual isomiRs using hybridization methods such as microarray and PCR are made difficult by the shortness of isomiRs sequences and their similarity to canonical miRNA (46). In contrast, the NGS platform is not affected by these characteristics and facilitates the identification of isomiRs. Indeed, our study demonstrated that isomiR abundance differed from that of the canonical miRNA and that

expression levels in serum also differed between BC patients and cancer-free individuals.

miR-21-5p has been reported as an oncogenic miRNAs related to cell proliferation and tumor invasion (47). Increased expression of circulating miR-21-5p has been observed in various cancers, including BC, and is associated with lymph node metastasis or prognosis (48, 49).

Although few studies have evaluated the expression of isomiRs, aberrant expression of isomiR of miR-21-5p (3' addition C) in tissue of colon cancer was recently reported (46). IsomiR of miR-21-5p (3' addition C) may not be BC-specific however, our data raise the possibility that the significant difference in the isomiR of miR-21-5p (3' addition C) in serum can serve as a precise biomarker for BC detection and warrants further functional investigation.

In addition to using increases in specific isomiR as a biomarker, we also found that canonical miRNA, miR-23a-3p in our study, is expressed abundantly in BC and also has biomarker potential. Upregulated miR-23a-3p has been observed in BC, and plays a role in cancer progression through the MAPK pathway (50, 51). Although the mechanism by which individual isomiR works in the gene regulation network remains poorly understood, our results suggest the importance of comprehensive analysis of miRNA expression, including isomiRs, as a way to provide more accurate biological information than analysis of canonical miRNAs alone.

In addition, we also identified the importance of tRF-Lys (TTT) as a small RNA that displayed significantly high expression levels in BC patients. tRFs are a novel class of small RNAs that

play regulatory roles in several biological processes and have been associated with cancer (52).

With the development of high-throughput sequencing technology, aberrant expression of tRFs has been identified in tissue and blood as well as miRNAs (29, 53). Of note, tRFs are the most abundant small RNA in serum, more than miRNAs (54). Indeed, expression levels of circulating tRFs were more abundant than miRNAs and other ncRNA fragments in our study. Our study is the first to report the increased expression of tRF-Lys (TTT) in the serum of BC patients, and the significant difference in expression in these patients introduces tRF-Lys (TTT) as a novel actor which requires further exploration.

An important aspect of our study is its evaluation of small RNA profiles within EVs from serum and cell culture media. Considering EV's active function as an intercellular messenger, an increasing number of studies have evaluated EV miRNAs rather than miRNA in whole serum or plasma as cancer biomarkers (55). EVs are released from various normal and cancer cells, and those in blood circulation are accordingly derived from various cell types (56). Importantly, the composition of EVs are known to be origin-specific, providing potential advantage of biomarkers (57). We observed high concentration of serum-derived EVs in BC patients compared to control as shown in Figure 5C. This result is supported by the finding that showed the increased number of EVs released from tumor cells into bloodstream (58). In addition, we found increased expression levels of isomiR of miR-21-5p (3' addition C) and miR-23a-3p in

serum EVs from BC patients, albeit that we did not analyze EV small RNA in all serum samples. In this study, we calculated RPM values for NGS analysis and thus we could not conclude whether the contributor of up-regulated expression of 2 miRNAs in serum-derived EVs was due to an increase of loaded miRNAs per particle and/or an increased amount of EV secretion. It might be considered as an ideal biomarker for cancer detection that holds the concept of highly encapsulated small RNAs within EVs involved in oncogenesis at high concentration level, however, it must be taken into consideration that the occupancy level of small RNAs in EVs required to mediate communication remains unclear (59). Considering the utility of diagnostic biomarkers using total serum, this may not impact on our findings that suggest intriguing ability of 2 miRNAs as biomarkers for BC detection. Although we could not exclude the possibility that our identified small RNAs were not directly related to BC using serum EV samples, our additional approach for small RNA profiling of EVs derived from cell culture media may complement the availability of 2 miRNAs based on their high expression level in BC cell lines. In contrast, our results also show that tRF-Lys (TTT) are not aberrantly included in EVs but circulate in serum. Further studies of small RNA expression in supernatant excluding EVs may help to describe the discrepant findings for tRF-Lys (TTT) between serum and EVs so that the different circulating form might be considered as the possible cause of inconsistency. However, we were unable to do this additional study due to the lack of serum

sample volume and the technical inability to obtain supernatant after using the EV isolation kit.

While the use of EV small RNAs in serum for BC detection appears warranted, practical adoption is hampered by the lack of uniform standards for the definition and isolation of EVs.

Methods for EV isolation vary among studies, which may cause discrepant results and lack of reproducibility. Furthermore, practical application will require a simple and efficient system that can detect cancer without an additional EV isolation step. Clinical use therefore requires the construction of a distinctive model using circulating small RNAs, as in our study.

Several limitations of our study warrant mention. First, participant numbers were small and did not include patients with benign breast tumors. Confirmation of biomarker accuracy and the clinical utility of our diagnostic model therefore requires larger studies conducted in multiple centers, including patients with benign breast tumors. Second, while a study using both serum and tissue samples would be desirable, we could not obtain tissue samples of participant suitable for experimentation. Further prospective studies are needed to evaluate the association of small RNA between serum samples and tissues. Additionally, the functional studies of small RNAs could be further investigated to improve the robustness of our results. Finally, we used the commercially available isolation kit for EV isolation in our study. Ultracentrifugation is commonly used for EV isolation as the gold standard method in research setting (60); however, we could not obtain enough amount of blood samples for ultracentrifugation. Thus, we

employed the alternative method that works with small sample volumes for higher recovery of EVs. An important factor that should be considered for EV characterization isolated using the kit is lipoprotein, which may affect EV purification (60). In our study, lipoprotein was detected in serum-derived EVs that may interfere the analysis of EV small RNAs. We acknowledge our method requires improvement for analysis of serum-derived EVs; however, following TEM analysis and positive markers by western blotting revealed the presence of EVs and EVs derived from cell culture media did not affected by lipoproteins, our identified small RNAs in serum serve as novel biomarker for BC detection.

In conclusion, this study found that small RNA expression in serum samples significantly differed between BC patients and cancer-free individuals. Comprehensive analysis using NGS identified 3 circulating small RNAs that showed significantly up-regulated expression in BC, suggesting a novel biomarker for BC detection. Our constructed classifier based on expression level of circulating small RNAs can distinguish BC with high diagnostic accuracy rate. The robustness of our diagnostic model was enhanced by further investigation of EV small RNAs in serum. Even with limited data from only 2 BC cell lines, analysis of EV expression in cells allowed us to construct a reliable model comprising circulating small RNAs.

Acknowledgements

This study was supported by the “Development of Diagnostic Technology for Detection of miRNA in Body Fluids” grant from the Japan Agency for Medical Research and Development and New Energy and Industrial Technology Development Organization. The authors thank Drs. Yuichiro Hamai and Takashi Amano at Okimi-Hamai Hospital for providing serum samples from cancer-free individuals. We also thank all members of the Department of Surgical Oncology and Drs Saori Fukunaga, Yoshitomo Shiroma, Shigeyuki Teranishi, and Kimiyoshi Yano at the Graduate School of Biomedical & Health Sciences at Hiroshima University for their helpful discussions.

Disclosures

Prof. Hidetoshi Tahara is representative director of a university-originated venture, MiRTeL Co.LTD. The family member, Kanoko Tahara is employee of MiRTeL Co. LTD. The remaining authors declare no potential conflict of interest.

References

1. Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, et al. Risk Factors and Preventions of Breast Cancer. *International journal of biological sciences*. 2017;13(11):1387-97.
2. Gotzsche PC, Jorgensen KJ. Screening for breast cancer with mammography. *The*

Cochrane database of systematic reviews. 2013(6):Cd001877.

3. Baum M. Should routine screening by mammography be replaced by a more selective service of risk assessment/risk management? *Women's health* (London, England). 2010;6(1):71-6.

4. Pace LE, Keating NL. A systematic assessment of benefits and risks to guide breast cancer screening decisions. *Jama*. 2014;311(13):1327-35.

5. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, et al. Mammographic density and the risk and detection of breast cancer. *The New England journal of medicine*. 2007;356(3):227-36.

6. Lee K, Kim H, Lee JH, Jeong H, Shin SA, Han T, et al. Retrospective observation on contribution and limitations of screening for breast cancer with mammography in Korea: detection rate of breast cancer and incidence rate of interval cancer of the breast. *BMC women's health*. 2016;16(1):72.

7. del Carmen MG, Halpern EF, Kopans DB, Moy B, Moore RH, Goss PE, et al. Mammographic breast density and race. *AJR American journal of roentgenology*. 2007;188(4):1147-50.

8. Li SP, Lin ZX, Jiang XY, Yu XY. Exosomal cargo-loading and synthetic exosome-mimics as potential therapeutic tools. *Acta pharmacologica Sinica*. 2018;39(4):542-51.

9. Fais S, O'Driscoll L, Borrás FE, Buzas E, Camussi G, Cappello F, et al. Evidence-Based Clinical Use of Nanoscale Extracellular Vesicles in Nanomedicine. *ACS nano*. 2016;10(4):3886-99.
10. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. *The Journal of cell biology*. 2013;200(4):373-83.
11. Storz G. An expanding universe of noncoding RNAs. *Science (New York, NY)*. 2002;296(5571):1260-3.
12. Vickers KC, Sethupathy P, Baran-Gale J, Remaley AT. Complexity of microRNA function and the role of isomiRs in lipid homeostasis. *Journal of lipid research*. 2013;54(5):1182-91.
13. Neilsen CT, Goodall GJ, Bracken CP. IsomiRs--the overlooked repertoire in the dynamic microRNAome. *Trends in genetics : TIG*. 2012;28(11):544-9.
14. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids--the mix of hormones and biomarkers. *Nature reviews Clinical oncology*. 2011;8(8):467-77.
15. Reid G, Kirschner MB, van Zandwijk N. Circulating microRNAs: Association with disease and potential use as biomarkers. *Critical reviews in oncology/hematology*. 2011;80(2):193-208.

16. Zaratiegui M, Irvine DV, Martienssen RA. Noncoding RNAs and gene silencing. *Cell*. 2007;128(4):763-76.
17. Bartel DP. MicroRNAs: target recognition and regulatory functions. *Cell*. 2009;136(2):215-33.
18. Shen Y, Yu X, Zhu L, Li T, Yan Z, Guo J. Transfer RNA-derived fragments and tRNA halves: biogenesis, biological functions and their roles in diseases. *Journal of molecular medicine (Berlin, Germany)*. 2018;96(11):1167-76.
19. Wu W, Sun M, Zou GM, Chen J. MicroRNA and cancer: Current status and prospective. *International journal of cancer*. 2007;120(5):953-60.
20. Weiland M, Gao XH, Zhou L, Mi QS. Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases. *RNA biology*. 2012;9(6):850-9.
21. Schrauder MG, Strick R, Schulz-Wendtland R, Strissel PL, Kahmann L, Loehberg CR, et al. Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. *PloS one*. 2012;7(1):e29770.
22. Mishra S, Srivastava AK, Suman S, Kumar V, Shukla Y. Circulating miRNAs revealed as surrogate molecular signatures for the early detection of breast cancer. *Cancer letters*. 2015;369(1):67-75.
23. Zhang K, Wang YW, Wang YY, Song Y, Zhu J, Si PC, et al. Identification of microRNA

biomarkers in the blood of breast cancer patients based on microRNA profiling. *Gene*. 2017;619:10-20.

24. Jia Y, Chen Y, Wang Q, Jayasinghe U, Luo X, Wei Q, et al. Exosome: emerging biomarker in breast cancer. *Oncotarget*. 2017;8(25):41717-33.

25. Hannafon BN, Trigos YD, Calloway CL, Zhao YD, Lum DH, Welm AL, et al. Plasma exosome microRNAs are indicative of breast cancer. *Breast cancer research : BCR*. 2016;18(1):90.

26. Kumar P, Kuscu C, Dutta A. Biogenesis and Function of Transfer RNA-Related Fragments (tRFs). *Trends in biochemical sciences*. 2016;41(8):679-89.

27. Guo L, Chen F. A challenge for miRNA: multiple isomiRs in miRNAomics. *Gene*. 2014;544(1):1-7.

28. Yu F, Pillman KA, Neilsen CT, Toubia J, Lawrence DM, Tsykin A, et al. Naturally existing isoforms of miR-222 have distinct functions. *Nucleic acids research*. 2017;45(19):11371-85.

29. Dhahbi JM, Spindler SR, Atamna H, Boffelli D, Martin DI. Deep Sequencing of Serum Small RNAs Identifies Patterns of 5' tRNA Half and YRNA Fragment Expression Associated with Breast Cancer. *Biomarkers in cancer*. 2014;6:37-47.

30. Gospodarowicz MK, Brierley JD, Wittekind C. TNM classification of malignant

tumours: John Wiley & Sons; 2017.

31. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2013;31(31):3997-4013.
32. Nakamura K, Kusama K, Bai R, Sakurai T, Isuzugawa K, Godkin JD, et al. Induction of IFNT-Stimulated Genes by Conceptus-Derived Exosomes during the Attachment Period. *PloS one*. 2016;11(6):e0158278.
33. Kozomara A, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. *Nucleic acids research*. 2014;42(Database issue):D68-73.
34. Chan PP, Lowe TM. GtRNADB 2.0: an expanded database of transfer RNA genes identified in complete and draft genomes. *Nucleic acids research*. 2016;44(D1):D184-9.
35. Chan PP, Lowe TM. GtRNADB: a database of transfer RNA genes detected in genomic sequence. *Nucleic acids research*. 2009;37(Database issue):D93-7.
36. Zerbino DR, Achuthan P, Akanni W, Amode MR, Barrell D, Bhai J, et al. Ensembl 2018. *Nucleic acids research*. 2018;46(D1):D754-d61.
37. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring

and therapeutics. A comprehensive review. *EMBO molecular medicine*. 2012;4(3):143-59.

38. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2007;25(33):5287-312.

39. Ambros V. The functions of animal microRNAs. *Nature*. 2004;431(7006):350-5.

40. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell*. 2004;116(2):281-97.

41. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. *Nature*. 2005;435(7043):834-8.

42. Bartels CL, Tsongalis GJ. MicroRNAs: novel biomarkers for human cancer. *Clinical chemistry*. 2009;55(4):623-31.

43. Cloonan N, Wani S, Xu Q, Gu J, Lea K, Heater S, et al. MicroRNAs and their isomiRs function cooperatively to target common biological pathways. *Genome biology*. 2011;12(12):R126.

44. Llorens F, Banez-Coronel M, Pantano L, del Rio JA, Ferrer I, Estivill X, et al. A highly expressed miR-101 isomiR is a functional silencing small RNA. *BMC genomics*. 2013;14:104.

45. Salem O, Erdem N, Jung J, Munstermann E, Worner A, Wilhelm H, et al. The highly expressed 5'isomiR of hsa-miR-140-3p contributes to the tumor-suppressive effects of miR-140 by reducing breast cancer proliferation and migration. *BMC genomics*. 2016;17:566.
46. Wu CW, Evans JM, Huang S, Mahoney DW, Dukek BA, Taylor WR, et al. A Comprehensive Approach to Sequence-oriented IsomiR annotation (CASMIR): demonstration with IsomiR profiling in colorectal neoplasia. *BMC genomics*. 2018;19(1):401.
47. Feng YH, Tsao CJ. Emerging role of microRNA-21 in cancer. *Biomedical reports*. 2016;5(4):395-402.
48. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. *RNA (New York, NY)*. 2008;14(11):2348-60.
49. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. *Proceedings of the National Academy of Sciences of the United States of America*. 2006;103(7):2257-61.
50. Eissa S, Matboli M, Shehata HH. Breast tissue-based microRNA panel highlights microRNA-23a and selected target genes as putative biomarkers for breast cancer. *Translational research : the journal of laboratory and clinical medicine*. 2015;165(3):417-27.
51. Li X, Liu X, Xu W, Zhou P, Gao P, Jiang S, et al. c-MYC-regulated miR-23a/24-2/27a

cluster promotes mammary carcinoma cell invasion and hepatic metastasis by targeting

Sprouty2. *The Journal of biological chemistry*. 2013;288(25):18121-33.

52. Anderson P, Ivanov P. tRNA fragments in human health and disease. *FEBS letters*. 2014;588(23):4297-304.

53. Olvedy M, Scaravilli M, Hoogstrate Y, Visakorpi T, Jenster G, Martens-Uzunova ES. A comprehensive repertoire of tRNA-derived fragments in prostate cancer. *Oncotarget*. 2016;7(17):24766-77.

54. Lee YS, Shibata Y, Malhotra A, Dutta A. A novel class of small RNAs: tRNA-derived RNA fragments (tRFs). *Genes & development*. 2009;23(22):2639-49.

55. Endzelins E, Berger A, Melne V, Bajo-Santos C, Sobolevska K, Abols A, et al. Detection of circulating miRNAs: comparative analysis of extracellular vesicle-incorporated miRNAs and cell-free miRNAs in whole plasma of prostate cancer patients. *BMC cancer*. 2017;17(1):730.

56. Yanez-Mo M, Siljander PR, Andreu Z, Zavec AB, Borrás FE, Buzas EI, et al. Biological properties of extracellular vesicles and their physiological functions. *Journal of extracellular vesicles*. 2015;4:27066.

57. Soung YH, Nguyen T, Cao H, Lee J, Chung J. Emerging roles of exosomes in cancer invasion and metastasis. *BMB reports*. 2016;49(1):18-25.

58. Melo SA, Sugimoto H, O'Connell JT, Kato N, Villanueva A, Vidal A, et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. *Cancer cell*. 2014;26(5):707-21.
59. Chevillet JR, Kang Q, Ruf IK, Briggs HA, Vojtech LN, Hughes SM, et al. Quantitative and stoichiometric analysis of the microRNA content of exosomes. *Proceedings of the National Academy of Sciences of the United States of America*. 2014;111(41):14888-93.
60. Doyle LM, Wang MZ. Overview of Extracellular Vesicles, Their Origin, Composition, Purpose, and Methods for Exosome Isolation and Analysis. *Cells*. 2019;8(7).

Figure Legends

Figure 1. Schematic overview of the study.

Figure 2. Comparison of normalized reads of 3 significantly upregulated small RNAs in the validation cohort ($*p < 0.01$).

Figure 3. Comparison of IsomiR abundance in serum from BC patients (n=78) and cancer-free individuals (n=72). The 5 most abundant forms of miRNA are presented in the Y axis. miR-21-5p (A), miR-23a-3p (B).

Figure 4. Diagnostic utility of 3 small RNAs for BC detection. Receiver operating characteristic curve analysis (A), relative levels using small RNAs in BC patients and cancer-free individuals (N) by BC stage ($*p < 0.01$) (B), relative levels using small RNAs in BC patients and N by BC subtype ($*p < 0.01$) (C), relative levels using small RNAs in BC patients by IHC analysis in patients with invasive BC (D), and comparison of diagnostic values among serum markers CEA and CA15-3, and our constructed model (E).

Figure 5. Characterization of EVs isolated with an exosome isolation kit. TEM analysis of EVs (A). Western blot analysis of exosomal markers CD9 and TSG101 (B). Contribution of nanoparticles of EVs (C), and total concentration of each EV (D). ApoB as a marker of lipoproteins by western blotting (E).

Figure 6. Expression of identified small RNAs in EVs derived from serum of 32 BC patients and

20 cancer-free individuals (N), and from cell culture media of 184-h TERT, MCF7, and MDA-MB-231 ($*p < 0.01$).

Tables and Figures

Table 1. Clinicopathological characteristics of participants.

	Screening phase (n = 75)		Validation phase (n = 75)	
	BC (n = 39)	N (n = 36)	BC (n = 39)	N (n = 36)
Median age (range), years	57 (40-80)	65 (42-80)	50 (26-78)	62 (25-80)
Stage				
0	6 (15.4%)	-	5 (12.8%)	-
1	13 (33.3%)	-	15 (38.5%)	-
2	17 (43.6%)	-	14 (35.9%)	-
3	3 (7.7%)	-	5 (12.8%)	-
Estrogen receptor				
positive	28 (84.8%)	-	29 (85.3%)	-
negative	5 (15.2%)	-	5 (14.7%)	-
Progesterone receptor				
positive	26 (78.8%)	-	26 (76.5%)	-
negative	7 (21.2%)	-	8 (23.5%)	-
HER2				
positive	2 (6.1%)	-	3 (8.8%)	-
negative	31 (93.9%)	-	31 (91.2%)	-

BC: Breast cancer, N: Control, HER2: human epidermal growth factor receptor 2

Table 2. Significantly upregulated small RNAs in the serum of BC group compared to N group in both screening and validation phase.

Sequence	L	Small RNA	Screening phase				Validation phase			
			BC mean reads	N mean reads	FC	p	BC mean reads	N mean reads	FC	p
<i>miRNAs</i>										
UAGCUUAUCAGACUGAUGUUGAC	23	isomiR of miR-21-5p (3' addition C)	1835	708	2.59	< 0.01	1722	841	2.05	< 0.01
AUCACAUUGCCAGGGAUUUCC	21	miR-23a-3p	2635	1248	2.11	< 0.01	2669	1077	2.48	< 0.01
UUCAAGUAAUCCAGGAUAGGCU	22	miR-26a-1//miR-26a-2	1011	466	2.17	< 0.01	848	602	1.41	0.02
GUCAGUUUGUCAAAUACCCCA	21	isomiR of miR-223-3p (5' deletion U)	2573	952	2.70	< 0.01	2752	1726	1.59	0.02
GUCAGUUUGUCAAAUACCCCAA	22	isomiR of miR-223-3p (5' deletion U and 3' addition A)	6644	2699	2.46	0.01	7131	5012	1.42	0.05
UGUCAGUUUGUCAAAUACCCCAA	23	isomiR of miR-223-3p (3' addition A)	22652	11286	2.01	0.04	24779	16169	1.53	0.02
<i>tRFs</i>										
GCGCCGCUGGUGUAGUGGUAUCAUGCAAGA	30	tRF-Gly (CCC)	62251	28598	2.18	< 0.01	59129	57599	1.03	0.92
GCGCCGCUGGUGUAGUGGUAUCAUGCAAGAU	31	tRF-Gly (CCC)	48196	7331	6.57	< 0.01	53153	34470	1.54	0.07
GCGCCGCUGGUGUAGUGGUAUCAUGCAAGAUU	32	tRF-Gly (CCC)	78465	12471	6.29	< 0.01	85170	53442	1.59	0.02
AGCAGAGUGGCGCAGCGGAAGCGUGCUGGGC	31	tRF-iMet (CAT)	37525	11628	3.23	< 0.01	40779	29984	1.36	0.04
GCCCCGAUAGCUCAGUCGGUAGAGCAUCAGAC	32	tRF-Lys (TTT)	19234	6941	2.77	< 0.01	22138	10059	2.20	< 0.01


tRF-Gly (CCC): Homo_sapiens_tRNA-Gly-CCC-2-1//Homo_sapiens_tRNA-Gly-CCC-2-2, tRF-iMet (CAT): Homo_sapiens_tRNA-iMet-CAT-1-1//Homo_sapiens_tRNA-iMet-CAT-1-2//Homo_sapiens_tRNA-iMet-CAT-1-3//Homo_sapiens_tRNA-iMet-CAT-1-4//Homo_sapiens_tRNA-iMet-CAT-1-5//Homo_sapiens_tRNA-iMet-CAT-1-6//Homo_sapiens_tRNA-iMet-CAT-1-7//Homo_sapiens_tRNA-iMet-CAT-1-8//Homo_sapiens_tRNA-iMet-CAT-2-1, tRF-Lys (TTT): Homo_sapiens_tRNA-Lys-TTT-3-1//Homo_sapiens_tRNA-Lys-TTT-3-2//Homo_sapiens_tRNA-Lys-TTT-3-3//Homo_sapiens_tRNA-Lys-TTT-3-4//Homo_sapiens_tRNA-Lys-TTT-3-5//Homo_sapiens_tRNA-Lys-TTT-5-1

Table 3. Diagnostic accuracy, sensitivity, and specificity for discriminating BC patients from cancer-free individuals.

Small RNA	Screening phase			Validation phase		
	accuracy (%)	sensitivity (%)	specificity (%)	accuracy (%)	sensitivity (%)	specificity (%)
isomiR of miR-21-5p (3' addition C)	80.0	76.9	83.3	69.3	53.8	86.1
miR-23a-3p	78.7	69.2	88.8	89.3	82.1	97.2
tRF-Lys (TTT)	77.3	74.4	80.6	72.0	71.8	72.2
combination of three small RNAs above	89.3	92.3	86.1	89.3	79.5	100

Figure 1. Schematic overview of the study.

A



**Identification of 11 up-regulated small ncRNAs in BC patients
Construction of model for BC diagnosis using 3 up-regulated small ncRNAs**

B




Figure 2. Comparison of normalized reads of 3 significantly upregulated small RNAs in validation cohort (* $p < 0.01$).




Figure 3. IsomiR abundance in serum compared between BC patients (n=78) and cancer-free individuals (n=72). The 5 most abundant forms of miRNAs are presented in Y axis.





Figure 4. Diagnostic utility of 3 small RNAs for BC detection. Receiver operating characteristic curve analysis (A), relative levels using small RNAs in BC patients and cancer-free individuals (N) by BC stage (*p < 0.01) (B), relative levels using small RNAs in BC patients and N by BC subtype (*p < 0.01) (C)




Figure 4. Diagnostic utility of 3 small RNAs for BC detection. relative levels using small RNAs in BC patients by IHC analysis in patients with invasive BC (D), and comparison of diagnostic values among serum markers CEA and CA15-3, and our constructed model (E).







Figure 5. Characterization of EVs isolated with an exosome isolation kit. TEM analysis of EVs (A). Western blot analysis of exosomal markers CD9 and TSG101 (B). Contribution of nanoparticles of EVs (C), and total concentration of each EV (D). ApoB as a marker of lipoproteins by western blotting (E).


A




B



C



D



E




Figure 6. Expression of identified small RNAs in EVs derived from serum of 32 BC patients and 20 cancer-free individuals (N), and from cell culture media of 184-h TERT, MCF7, and MDA-MB-231 (* $p < 0.001$, ** $p < 0.01$).

